Although their utility has been most documented in the treatment of NIU and NIU-related macular edema, the use of IL-6 inhibitors might be extended to inflammatory CME in the context of complications from cataract surgery, acute retinal necrosis, and autoimmune retinopathy. The gene discussed is IL6; the disease is acute retinal necrosis syndrome.